Monitor the final terms of the offering, including the number of ADSs and the public offering price, once the prospectus supplement is completed. The use of proceeds for pipeline development and working capital suggests a focus on advancing the company's product candidates.
Price Chart
Executive Summary
Legend Biotech Corp is filing a preliminary prospectus supplement for a proposed $225,000,000 offering of American Depositary Shares (ADSs) representing ordinary shares. The offering is underwritten by Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities. The company intends to use the net proceeds to fund the development of its pipeline programs, including LB2501, and for working capital and other general corporate purposes. The filing is a preliminary prospectus supplement subject to completion, and the specific terms of the offering, including the number of ADSs and the public offering price, are not yet finalized.
Key Facts
- Legend Biotech Corp is offering American Depositary Shares (ADSs) representing ordinary shares.
- The offering is for $225,000,000.
- Each ADS represents two ordinary shares.
- The ADSs are listed on the Nasdaq Global Select Market under the symbol LEGN.
- The last reported sale price of the ADSs on Nasdaq was $33.38 per ADS.
- The net proceeds from the offering will be used to fund the development of pipeline programs, including LB2501, and for working capital and other general corporate purposes.
- The offering is subject to completion and is dated June 17, 2026.
Financial Impact
The offering is for $225,000,000 in American Depositary Shares. The specific number of ADSs and the public offering price are not yet determined.
Risk Factors
- The offering is subject to completion and may be changed.
- The public offering price may be at a discount to the current market price.
- The company has broad discretion in the use of proceeds.
- Investors will suffer immediate dilution of their investment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-274318 |
| Document: 0001193125-26-274318-index-headers.html | 0001193125-26-274318 |
| Document: 0001193125-26-274318-index.html | 0001193125-26-274318 |
| Document: 0001193125-26-274318.txt | 0001193125-26-274318 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 6-K | $19.80 | awaiting T+20 | — | $21.42 (+8.18%) |
Oct 13, 2026 14d ago | 6-K | $17.88 | awaiting T+20 | — | $21.42 (+19.80%) |
Sep 29, 2026 27d ago | 144 | $18.82 | awaiting T+20 | — | $21.42 (+13.82%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $21.42 (+12.09%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $21.42 (+12.09%) |
Sep 15, 2026 6w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $21.42 (+21.22%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $21.42 (+15.60%) |
Aug 11, 2026 11w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $21.42 (−1.88%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $21.42 (−11.16%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $21.42 (+11.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers